CME Group reports FY 2025 market data revenue of USD 0.80 billion, up 13%

Reuters
02/04
CME Group reports FY 2025 market data revenue of USD 0.80 billion, up 13%

CME Group reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For FY 2025, the company posted total revenue of USD 6.52 billion, marking a 6% increase. Operating income for the year was USD 4.20 billion. Net income reached USD 4.10 billion, with diluted earnings per share at USD 11.16. On an adjusted basis, net income was USD 4.09 billion and diluted earnings per share were USD 11.20. For Q4 2025, CME Group recorded revenue of USD 1.65 billion and operating income of USD 1.00 billion. Net income for the quarter was USD 1.20 billion, with diluted earnings per share of USD 3.24. Adjusted net income for Q4 was USD 1.01 billion, while adjusted diluted earnings per share stood at USD 2.77. CME Group achieved record annual market data revenue of USD 803 million, up 13% for the year. The company reported record average daily volume of 28.1 million contracts in 2025, with commodities trading volume growing 12% and financials trading volume rising 5%. In Q4, CME Group delivered its second-highest quarterly revenue and the highest Q4 volume on record, according to Chairman and CEO Terry Duffy, who attributed the performance to continued strong client demand in a "risk-always-on environment."

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CME Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: AQ78236) on February 04, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10